Minerva Neurosciences, Inc. (NERV) Balance Sheet

The consistent expansion of the accumulated deficit suggests that the company is consuming capital at a rate that far outpaces its ability to generate value. This trajectory indicates that the balance sheet is becoming increasingly fragile, leaving little room for error as the company navigates its regulatory challenges.

The introduction of debt into the capital structure during a period of zero revenue generation warrants close monitoring by investors. This reliance on debt financing may indicate that traditional equity markets are becoming less receptive or that management is attempting to preserve equity value at the cost of increased interest obligations.

While the current ratio appears high due to the nature of current liabilities, the absolute cash balance is the more critical metric for a pre-revenue firm. The rapid depletion of these reserves suggests that the company may face a liquidity crunch if regulatory milestones are not met in the immediate future.